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Mixed-Methods Study Identifying Key Intervention
Targets to Improve Participation in Daily Living
Activities in Primary Sj€ogren’s Syndrome Patients
KATIE L. HACKETT ,1 KATHERINE H. O. DEANE,2 JULIA L. NEWTON,3 VINCENT DEARY,4
SIMON J. BOWMAN ,5 TIM RAPLEY ,6 AND WAN-FAI NG ,3 ON BEHALF OF THE UNITED KINGDOM
PRIMARY SJ€OGREN’S SYNDROME REGISTRY
Objective. Functional ability and participation in life situations are compromised in many primary Sj€ogren’s syndrome
(SS) patients. This study aimed to identify the key barriers and priorities to participation in daily living activities, in order
to develop potential future interventions.
Methods. Group concept mapping, a semiquantitative, mixed-methods approach was used to identify and structure ideas
from UK primary SS patients, adult household members living with a primary SS patient, and health care professionals.
Brainstorming generated ideas, which were summarized into a final set of statements. Participants individually arranged
these statements into themes and rated each statement for importance. Multidimensional scaling and hierarchical cluster
analysis were applied to sorted and rated data to produce visual representations of the ideas (concept maps), enabling iden-
tification of agreed priority areas for interventions.
Results. A total of 121 patients, 43 adult household members, and 67 health care professionals took part. In sum, 463 ideas were
distilled down to 94 statements. These statementswere grouped into 7 clusters: Patient Empowerment, Symptoms,Wellbeing, Access
and Coordination of Health Care, Knowledge and Support, Public Awareness and Support, and Friends and Family. Patient
Empowerment and Symptoms were rated as priority conceptual themes. Important statements within priority clusters indicate
patients should be taken seriously and supported to self-manage symptoms of oral and ocular dryness, fatigue, pain, and poor sleep.
Conclusion. Our data highlighted the fact that in addition to managing primary SS symptoms, interventions aiming to
improve patient empowerment, general wellbeing, access to health care, patient education, and social support are impor-
tant to facilitate improved participation in daily living activities.
INTRODUCTION
Primary Sj€ogren’s syndrome (SS) is a systemic autoimmune
disease characterized by sicca symptoms (1). Additionally,
extraglandular symptoms are commonly experienced (2),
including pain (3), sleep disturbances (4), fatigue (5), low
mood, and anxiety (6). These symptoms impact significantly
on quality of life (7,8), and many patients experience
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difficulty with participation (involvement in a life situation)
and undertaking functional activities (9,10). Examples
include problems with hygiene, grip, reach, eating, transfers,
mobility, vocational activities, and sexual activity (9–12).
There are currently no effective disease-modifying treat-
ments available, and management strategies typically focus
on symptom management. Pharmacologic treatments mainly
comprise topical treatments for dryness as well as systemic
treatments (13,14). However, such treatments have limited
effect on the quality of life (15–17).
Previous studies have demonstrated an association be-
tween functional impairment, disease activity, pain, and
fatigue (9,12). However, the key barriers to the perfor-
mance of daily function and participation among primary
SS patients have not been systematically studied. In
addition to gathering information from primary SS
patients, close family members can often provide useful
insight into factors that interfere with the daily activities
of the patients. Furthermore, in planning future interven-
tions that are effective and feasible to improve daily
function and participation of primary SS patients
(18,19), it is important to understand the perspective of
both potential users (primary SS patients), their support-
ers (people they live with), and the health care providers
who are likely to deliver the interventions in the future.
To our knowledge, there have been no published studies
investigating perspectives of other stakeholder groups
such as family members and health care professionals
(HCPs) who provide care to primary SS patients. The
aim of the study was to identify key barriers and priori-
ties to participation in daily living activities for primary
SS patients, as targets for future interventions.
SUBJECTS AND METHODS
We used group concept mapping (GCM) methodology (19) to
determine important key barriers to participation and daily
function in primary SS patients (Figure 1). Our specific
objectives were to identify barriers/facilitators to participa-
tion and performance of daily activities, structure the gener-
ated ideas into clusters or themes through a sorting exercise,
identify priority targets from the identified barriers/facilita-
tors and themed clusters, and compare similarities and dif-
ferences in priorities between different stakeholder groups.
GCM has been used in the rheumatic diseases to investi-
gate treatment for hip and knee osteoarthritis (20), to design
and develop online self-management interventions (21), and
in a program to prevent work disability in rheumatoid arthri-
tis patients (22). We have previously used this approach to
evaluate and plan improvements to a fatigue service (23).
The advantage of using this mixed-methods approach over
qualitative interviews or focus groups is that it mixes both
qualitative and quantitative methods, large numbers of
stakeholders can be consulted, and it provides a consensus
vision containing the prioritized ideas of all participants.
GCM is a semiquantitative, mixed-methods participatory
approach, which uses a combination of individual and
group processes (brainstorming, sorting, rating, and inter-
pretation) and multivariate statistical analyses (multidimen-
sional scaling and hierarchical cluster analysis). These
activities result in visual depictions of all stakeholders’
opinions in the form of concept maps. Participants add
quantitative values to qualitative statements that are
Figure 1. The 5 stages of group concept mapping.
Significance & Innovations
• Widespread stakeholder engagement with patients,
family, and health care professionals has identified
key priority themes, including Patient Empower-
ment, Symptoms, Wellbeing, and Access and Coor-
dination of Health Care, which can all be addressed
to improve functional ability in primary Sj€ogren’s
syndrome patients.
• The greatest priority is to take primary Sj€ogren’s
syndrome patients seriously and to provide indi-
vidualized support to self-manage the symptoms
of dryness, fatigue, pain, and poor sleep.
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gathered during the brainstorming phase, and these state-
ments can be interpreted in pattern matches and go-zones
and used in planning or evaluation studies (24). We pub-
lished the methods of this study a priori (25).
Participant groups. We recruited participants from 3
stakeholder groups. First, we recruited primary SS patients
(ages ≥18 years) who were members of the United Kingdom
Sj€ogren’s Syndrome Registry (UKPSSR) (26) and who
therefore fulfilled the American-European Consensus Group
classification criteria (27). The second group comprised
adults living with a primary SS patient (adult household
member [AHM]). The final group was HCPs working with
primary SS patients. We were granted approval to recruit
UKPSSR participants from 12 different sites in England. We
invited all UKPSSR participants at these sites to take part
via a mailed written invitation. An enclosed invitation was
included in the pack addressed to an AHM.
Data collection and analysis. We collected baseline age
and sex demographics from primary SS and AHM partici-
pants. Primary SS participants also indicated whether they
received disability benefits, the number of dependents living
with them, and their employment status, and they completed
a range of symptom scores (28–30). We asked HCPs to specify
which professional group they belonged to and complete a
measure of caregiver strain (31). This GCM study took place
in 5 discrete stages, and we gave participants the option to
complete the activities either online or on paper. Participants
could also choose to complete the brainstorming at a face-to-
face meeting at Newcastle.
Stage 1: ideas generation/brainstorming. We asked poten-
tial participants to respond to a focus prompt, an incom-
plete sentence that they could complete as many times as
they wished. The research team designed the focus prompt,
and it went through several iterations. The precise wording
of the focus prompt aimed to capture barriers and
facilitators to participation in daily activities for people
with primary SS, using lay terms. The focus prompt was:
“People with Sj€ogren’s could do more of the things they
want to do and have to do if. . .”
This process generated a list of statements/ideas from all
participants taking part in this stage of the study. A partici-
pant completing this exercise online could see statements
provided by other participants who had completed the
brainstorming activity previously. We added statements
received by participants in both the face-to-face meeting and
from postal replies to the online interface. Therefore, partici-
pants taking part online could also see the statements pro-
vided through the alternative data collection methods.
Brainstorming was continued until data saturation was
achieved (19,24), at which point no further unique ideas were
being generated through the brainstormed responses (32).
Stage 2: statement reduction. In this second stage, the
full list of statements was reduced to a shorter list of
unique ideas by several members of the research team
(KLH, VD, and TR). First, we split statements containing
more than one idea into separate statements. Next, we
applied a key word to each statement, formed groups of
statements containing the same key word, and considered
them in turn. We removed duplicate statements and
combined those that described the same or overlapping
idea (24). Subsequently, the refined statement list was
reviewed for syntax and readability by the research team,
2 patients with primary SS, and an AHM.
Stage 3: sorting activity. During the statement reduction
process, similar statements were considered together.
Applying a random number (i.e., 1–94) to each statement,
in effect, shuffled the statement list prior to the sorting
activity. The statements were numbered and randomized
within the software used for this GCM project (CS Global
MAX). The numbered statements were printed onto
individual cards and participants were asked to sort them
by creating piles of similar meaning statements. They were
asked to name each pile and to record the name of each
name and numbers of the statements contained within
each pile. Those opting to take part online could sort
statements into virtual piles.
Stage 4: rating activity. Participants were given a list of
the numbered statements and asked to rate them for im-
portance on a 1–5 Likert scale (where 1 = relatively unim-
portant and 5 = extremely important).
Stage 5: data analysis. Sorting and rating data were
analyzed in the CS Global MAX software. Multidimen-
sional scaling was applied to the sort data, which were
arranged into a similarity matrix to position each
statement in relation to others as a point on an X-Y axis.
This arrangement results in a 2-dimensional representation
of the statements, and each statement is represented by a
numbered point on a map. Multidimensional scaling
produces a stress value that indicates the goodness-of-fit of
the map with the raw data and stability within the overall
map. A stress value below 0.36 is preferred in concept
mapping studies (33). Statements that were frequently
sorted together end up being closely located near each
other on the map, as participants considered them to be
similar conceptually during the sorting activity.
Hierarchical cluster analysis (Ward’s method) was next
applied to the data, resulting in clusters of statements,
which were examined by the authors, who agreed on an
overall cluster solution through discussion. The software
suggests labels for clusters based on the names participants
give to their piles during the sorting exercise and
appropriate cluster names were selected using these
suggestions.
Importance ratings were considered at cluster level in a
pattern match, which demonstrates differences between
the importance ratings attributed by each participant
group to the clusters. Importance ratings were also consid-
ered at statement level in go-zones. These are scatter plots
comparing importance ratings for each statement within a
cluster for 2 groups. To make a visual 2-group comparison,
groups with both the lived experience of primary SS (pa-
tients and AHMs) were combined and compared with the
HCP group. A statement falling within the top right quad-
rant of the go-zone (demarcated by the mean importance
ratings for each group) indicates it is a priority for both
lived experience and HCP groups. Go-zones were gener-
ated for each cluster.
Ethics approval. Ethical approval was granted by the
Office for Research Ethics Committees Northern Ireland (13/
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NI/0190, IRAS Ref: 125562), and the study was registered on
the National Institute of Health Research Comprehensive
Clinical Research Network’s portfolio of noncommercial
studies (study ID: 15939).
RESULTS
Participant characteristics. From the 371 patients invited
to participate in the study, 49% replied that they would
like to take part, and 33% of patients completed 1 or more
stages of the GCM exercise. Flow diagrams of participants
through the study can be seen in Supplementary Figure 1,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23536/abstract. In
total, 231 participants took part, including 121 primary SS
patients, 43 AHMs, and 67 HCPs. The mean  SD age of
patient participants was 63  10 years, and 64  9.5
years for AHMs. Descriptive statistics demonstrating
demographic data for both primary SS and AHM
participants and patient symptom scores can be seen in
Table 1.
The HCP group included doctors (hospital doctors and
general practitioners), therapists (physiotherapists, occupa-
tional therapists, psychologists, and podiatrists), nurses,
and a service manager. A breakdown of professional groups
within the HCP participants can be seen in Supplementary
Figure 2, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23536/
abstract.
Statements from stages 1 and 2 and concept maps gener-
ated from stages 3, 4, and 5. Brainstorming generated 463
statements, which were distilled to a final set of 94 unique
statements. Multidimensional scaling resulted in a point
map with a stress value of 0.18. A 7-cluster solution was
agreed upon and contained the following named clusters:
Access and Coordination of Health Care, Knowledge and
Support, Public Awareness and Support, Friends and
Family, Symptoms, Patient Empowerment, and Wellbeing.
Table 1. Demographic information and symptom
scores for patients and demographics and Caregiver
Strain Index scores for adult household members*
Characteristics and measurements Values
Primary Sj€ogren’s syndrome patients
Age, mean  SD years 63.01  9.96
Years since diagnosis, mean  SD 10.15  7.21
Female, % 87
Live with another adult, % 73.50
Dependents living at home, % 18
Employment, %
Unemployed 5.7
Employed part-time 17
Employed full-time 14.8
Housewife/husband 46
Retired 57.9
Receiving disability benefits, %† 22
HADS anxiety (range 0–21) 7 (6)
HADS depression (range 0–21) 6 (5.7)
Pain VAS (range 0–100) 37.3 (27.4)
Fatigue VAS (range 0–100) 54.6 (29.2)
Mental fatigue VAS (range 0–100) 38.1 (28.7)
Dryness VAS (range 0–100) 56.7 (30)
Cognitive Failures Questionnaire
(range 0–100)
43.2 (18)
Improved Health Assessment
Questionnaire (range 0–100)
17.2 (36.7)
Adult household members
Female, % 37.2
Age, mean  SD years 62.7  11.4
Years since diagnosis of
household member, mean  SD
10.7  7.9
Caregiver Strain Index (range 0–13) 1 (3)
* Scores reported as median (interquartile range) unless otherwise
indicated. HADS = Hospital Anxiety and Depression Scale; VAS =
visual analog scale.
† Disability Living Allowance, Attendance Allowance, Personal
Independent Payments, Independent Living Fund, Employment
and Support Allowance or Incapacity Benefit, Caregiver Strain
Index.
Figure 2. Point cluster map showing the 7 themed clusters.
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Table 2. Mean importance ratings for the clusters and each of the numbered statements within each cluster
Statements and clusters Importance (1–5)
Cluster 1: Patient Empowerment 4.07
29. There was a cure 4.45
80. Felt they were being taken seriously 4.34
25. Have support to manage their symptoms themselves 4.22
58. Take their medication as prescribed 4.07
24. Have confidence to seek advice when needed 4.02
22. Look after their physical, emotional, and spiritual wellbeing 4.00
92. Were taught relaxation techniques 3.74
59. Have support with memory and concentration difficulties 3.73
Cluster 2: Symptoms 3.98
84. Their eyes were less dry 4.37
50. Have less pain 4.34
18. Were less fatigued 4.34
76. Fatigue was better managed/treated 4.34
32. Their vision was not impaired 4.32
61. Their eyes were more comfortable 4.31
71. Were able to sleep better 4.23
68. Have healthy teeth and/or comfortable dentures 4.17
69. Their throat was less dry 4.16
34. Swallowing was easier 4.10
82. Mouth and lips were less dry 4.07
72. Gastrointestinal (stomach and bowel) problems were managed 3.93
8. Were less prone to getting infections 3.89
31. Skin problems were treated 3.76
74. Were less breathless 3.64
77. Have more feeling in their mouth and lips 3.64
3. Did not have mouth sores or ulcers 3.61
36. Did not have sexual problems 3.54
27. Their skin was less dry 3.46
26. Their vagina was less dry 3.40
Cluster 3: Wellbeing 3.91
91. Keep their mind active 4.41
43. Have a positive attitude 4.41
90. Keep their body active 4.36
21. Feel in control of their symptoms 4.24
89. Develop good coping strategies 4.17
47. Exercise regularly 4.01
65. Learn to balance their activity and rest 3.96
46. They have better mobility 3.90
19. Could come to terms with their symptoms 3.84
6. They have a good diet 3.79
63. Could come to terms with their limitations 3.78
49. Could improve their concentration 3.75
52. Their mood was better 3.73
10. Were less stressed or worried 3.69
30. Could continue to drive 3.68
5. Could go out in the sun 2.86
Cluster 4: Access and Coordination of Health Care 3.89
54. There is good communication between clinicians 4.45
2. Have access to a range of good drug treatments 4.39
14. Have professional support during a flare of symptoms 4.37
1. Know who to contact when they have a flare of symptoms 4.32
85. Associated conditions are diagnosed and treated 4.31
15. Can see a consultant when needed 4.25
93. Their health care is better coordinated 4.20
4. Knew the range of available treatment options 4.18
79. Diagnosis was quick 4.17
66. There was more funding for specialist rheumatology services 4.12
7. There were one-stop Sj€ogren’s clinics with all relevant health care professionals available 4.02
62. Have access to a specialist nurse 3.91
40. Have an individualized treatment plan 3.90
(continued)
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The smallest cluster (Friends and Family) contained 6
statements and the largest (Access and Coordination of
Health Care), 22 statements. The point cluster map is shown
in Figure 2.
Statements belonging to the Patient Empowerment clus-
ter received the highest priority ratings of a possible 5, with
a mean  SD of 4.07  0.24, followed by the Symptoms
cluster with a mean  SD importance rating of 3.98  0.33
for each statement. The next most important clusters were
Wellbeing (mean  SD 3.91  0.38), Access and Coordina-
tion of Health Care (mean  SD 3.89  0.43), Knowledge
and Support (mean  SD 3.74  0.39), and Friends and
Family (mean  SD 3.69  0.30). The lowest rated cluster
was Public Awareness and Support (mean  SD 3.48 
0.36). Mean importance scores for each of the themed
clusters, together with the mean rating scores for the indi-
vidual statements within them can be viewed in Table 2.
Average importance rating scores for each cluster have
been broken down by stakeholder group and are shown in
Figure 3. Importance is rated 1–5, with 5 being the maxi-
mum possible score. Go-zones demonstrating the most
important statements within the clusters as determined by
all participants, as agreed by both health care staff and the
combined primary SS patient and household groups, are
shown in Figure 4. Priority statements are presented in the
upper right quadrants of each go-zone, which are demarked
with mean importance scores for each cluster. The remain-
ing go-zones can be seen in Supplementary Figure 3, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23536/abstract.
Table 2. (Cont’d)
Statements and clusters Importance (1–5)
45. There was better management of the side effects of drugs 3.88
56. Health care professionals would raise sensitive topics (e.g., sex and vaginal dryness) during
consultations
3.71
57. Professionals could direct them to support groups and charities 3.66
28. Have access to psychological support 3.49
70. Have access to occupational therapy 3.46
9. Have access to physiotherapy 3.39
88. Have access to complementary therapies or alternative remedies 3.23
44. There were diaries for recording symptoms and problems to bring to appointments with health care
professionals
3.16
81. Have access to hydrotherapy 2.96
Cluster 5: Knowledge and Support 3.74
20. There was more good research to test and develop treatments 4.45
13. There was more good research to understand the underlying causes 4.38
53. There was education on Sj€ogren’s for health care professionals 4.28
37. There was education on Sj€ogren’s for patients 3.97
75. There was information available on exercise and Sj€ogren’s 3.67
60. Have access to support and advice from other people with Sj€ogren’s 3.66
78. Have help with dental costs 3.65
67. Felt a family member or supporter would be welcome at their appointments 3.55
48. Have access to appropriate aids and adaptations in their homes 3.51
23. Felt a family member or supporter could be included in their care planning 3.48
11. Have Sj€ogren’s advice leaflets 3.44
38. Could access support to help set personal goals 3.44
12. There were appropriate aids and adaptations in the community 3.17
Cluster 6: Friends and Family 3.69
41. Have supportive family and friends 4.12
83. Family could understand the symptoms 3.83
94. Can explain to others what they can and cannot do 3.78
55. Could easily describe Sj€ogren’s to others 3.66
33. Friends and family include them in events 3.65
86. On a bad day people could tell by looking at them how they are feeling 3.10
Cluster 7: Public Awareness and Support 3.48
17. There was education about Sj€ogren’s for people who fund services 4.01
87. Those unable to work and/or who needed support to function were eligible for benefits 3.92
64. Employers were aware of things they could do in the workplace that are helpful for people with
Sj€ogren’s
3.85
51. There was education on Sj€ogren’s for family members 3.59
16. There was education about Sj€ogren’s for the general public 3.38
35. Public spaces were more Sj€ogren’s friendly, e.g., heated/lit/air conditioned differently 3.28
39. Have a disabled parking badge 3.14
73. Public transport was accessible 3.09
42. Have assistance with shopping, cleaning, etc. 3.04
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Patient Empowerment (8 statements). This cluster was
rated the most important cluster by both the primary SS and
AHM group. Within this cluster, the statements #80 “Felt
they were being taken seriously,” #25 “Have support to
manage their symptoms themselves,” and #29 “There was a
cure” all fell within the top right priority area of the go-zone.
Symptoms (20 statements). Statements within this cluster
all related to symptoms of primary SS. Statements within the
priority go-zone quadrant all related to symptoms of fatigue,
sleep disturbances, pain, and oral or ocular dryness.
Wellbeing (16 statements). Statements falling within the
priority quadrant include #21 “Feel in control of their
symptoms,” #43 “Have a positive attitude,” #65 “Learn to
balance their activity and rest,” #89 “Develop good coping
strategies,” and keeping both mind and body active (#90 and
#91). There was some disagreement regarding the priorities
of other statements within this cluster. The HCP group per-
ceived statement #19 “Could come to terms with their symp-
toms,” #63 “Could come to terms with their limitations,” and
#52 “Their mood was better” as being priority statements,
whereas those with the lived experience did not. Those in
the lived experience group rated a good diet, better mobility,
and regular exercise as priorities, whereas the HCP group
regarded these concepts as being less important.
Access and Coordination of Health Care (22 statements).
Statement #54 “There is good communication between
clinicians” was rated as the most important within this
cluster (Table 2). Other priority statements indicate that
one-stop clinics where a range of HCPs can be seen in 1
visit (#7), professional support during flares of the
Figure 4. Go-zones showing the most important statements within the most important clusters. A, Patient empowerment; B, Symptoms; C,
Wellbeing; D, Access and coordination of health care. For all 4 zones, health care staff: n = 61, and patients and household members: n = 124.
Figure 3. Pattern match depicting the mean importance ratings by participant group.
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condition (#14), clarity about who can be contacted if
symptoms do flare up (#1), and access to a consultant if
required (#15) were all deemed as being important factors.
Knowledge and Support (13 statements). The most
important statements within this cluster were those relating
to the need for more research to develop and test treatments
and research to understand the causes of the disease. These
were closely followed by statements relating to education
on primary SS for both HCPs and patients.
Friends and Family (6 statements). The most important
statement within this cluster was #41 “Have supportive
family and friends.” It was also deemed important that family
could understand primary SS symptoms (#83) and were able
to explain to others what they could or could not do (#94).
DISCUSSION
This study has identified factors that stakeholders have
deemed to interfere with performance of the daily activities
and participation in people with primary SS. These factors
have been grouped into conceptual cluster themes through
the sorting process undertaken by stakeholders and subse-
quent multiple dimensional scaling and cluster analysis.
The stress value of the point map generated during the mul-
tidimensional scaling process was low (0.18), demonstrating
stability within the concept map (ideal stress values should
fall below 0.39) (19). The factors were also prioritized at clus-
ter level, with individual priority factors identified within
each cluster through ascertaining the mean rating scores of
the individual statements within each of the clusters.
To our knowledge, only 1 published study has explored
patients’ viewpoints on determinants they consider to
interfere with their performance of daily activities and
quality of life (34). In this qualitative focus group study, the
authors found 3 broad domains containing 86 concepts.
These domains were the physical dimension, psychological
and emotional challenges, and social life and daily living.
The most commonly reported factors were from the physical
domain, and specific factors within this domain included
pain, dryness, shortness of breath and constipation (34).
However, only a small number of patients were involved
(n = 20), consequently, additional concepts may have been
missed. Moreover, the authors did not use a structured
approach to identify priority factors for intervention and
did not seek the perspectives of close family members of the
patients and health care providers. Our study has addressed
these limitations. Indeed, our data have identified addi-
tional concepts not previously reported, such as access to
and coordination of health care.
The primary SS participants who took part in this study
had a mean age of 63 years, similar to the average age of
UKPSSR participants (61 years) (7), which indicates that our
sample was representative of this cohort. The average
number of years since diagnosis in this study was 10. Con-
ceivably, newly diagnosed primary SS patients may have dif-
ferent needs, and a separate study is required to address this
possibility.
Our data show that the most important themed cluster
was Patient Empowerment. Patient empowerment is a pro-
cess where people improve their capacity to use their own
resources to navigate their health care and live well with
their chronic conditions (35). Others have described the
potential for patient empowerment as occurring at 3 levels:
at a patient level (e.g., patients’ rights, responsibilities, and
opportunities), a health care provider level (e.g., through
individual focused empowering intervention), and at a
health care system level (e.g., provision of group empower-
ing intervention) (36). The Patient Empowerment cluster
was located centrally in the map, indicating a connection
between this themed cluster and the surrounding clusters.
Priority statements within the Patient Empowerment cluster
demonstrate that in order to empower patients, HCPs need
to take them seriously (#80) and support them to manage
their symptoms themselves (#25). Multidisciplinary educa-
tion has been shown to empower rheumatoid arthritis pa-
tients to manage their condition and reduce disease activity
in the longer term (37). We hypothesize that addressing
these factors, for example through individualized interven-
tions supporting patients to manage their oral and ocular
dryness symptoms and with nonpharmacologic interven-
tions such as exercise (38,39), pain management (40,41),
and cognitive behavioral therapy for sleep disturbances (4),
patients may feel more patient empowered. Modes of deliv-
ering these interventions need to be considered, and digital
technologies, such as the use of mobile applications, can be
used to empower patients to take charge of their own health
(42) and used as an adjunct to face-to-face care.
The go-zone statements within the Wellbeing cluster
include potential facilitators to self-managing symptoms
such as fatigue and pain, including balancing activities and
rest (#65) and developing good coping strategies (#89).
These could be incorporated into a complex nonpharmaco-
logic behavior-change intervention package and ultimately
empower patients to self-manage their symptoms (36).
Within the Wellbeing cluster, there was also some disagree-
ment between the HCP and lived experience groups. HCPs
considered mood as being an important factor, whereas the
lived experience group did not prioritize this concern.
Other studies have demonstrated a relationship between
mood and quality of life (7), fatigue (43), and pain (44).
However, these studies have not been able to determine
whether mood is a consequence of these symptoms or a
causal factor. Our study shows that although HCPs regard
mood as a priority, patients prioritized other symptoms
first. This might be due to patients viewing their low mood
as being a consequence of these symptoms (34).
Our data also suggest that addressing the structure of
health care systems and how patients can access them
could influence patients’ ability to function better. For
instance, primary SS patients may see different specialists
because of the diverse symptomatology of the disease.
Allowing patients’ access to several specialists within a sin-
gle clinic would improve patient access and facilitate com-
munication between clinicians.
Our data are presented as priorities within each go-zone,
and these may be helpful when designing services and
interventions for primary SS patients. However, it is impor-
tant to stress that individual patients have different priori-
ties, and a personalized approach is essential. To provide a
personalized approach, holistic and multidisciplinary care
is required. Embedding access to multidisciplinary support
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within clinical services (and addressing the priority state-
ments within the Access and Coordination of Health Care
cluster) would facilitate individualized care.
This study is not without limitations. Only 33% of patient
participants invited to take part in the study went on to com-
plete one or more stages of the GCM activities. We therefore
cannot rule out possible selection bias. However, the mean
age of participants in this study (63 years) is similar to the
age of a recent study which included the majority of the
UKPSSR cohort (mean age 61 years) (7). Secondly, 13% of
the primary SS patients who took part in this study were
male, which is slightly greater than the proportion of males
(9%) reported in a recent meta-analysis of primary SS stud-
ies that included 7,888 participants (45). We therefore com-
pared differences in importance ratings for each cluster
between male and female primary SS participants (males
n = 10, females n = 83) by generating a further pattern match,
which revealed no differences in importance ratings between
males and females (r = 0.99). Therefore, despite a relatively
greater proportion of male primary SS patients taking part in
this study, there was a very high level of agreement between
males and females, and the increased male representation
did not influence the overall priority scores.
In conclusion, our study has identified several key
areas as targets for planning future interventions to sup-
port improvements in daily function and participation in
primary SS patients. Empowering patients by taking their
health concerns seriously and supporting them to self-
manage their condition is the greatest priority.
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